Genitourinary Cancer,RCC (Renal Cell Carcinoma) Phase 2 LITESPARK-004: Belzutifan, a HIF-2α Inhibitor, for VHL Disease-Associated Neoplasms Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Telaglenastat Plus Cabozantinib vs. Placebo Plus Cabozantinib in Advanced RCC Patients:CANTATA Phase 2 Trial Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Phase III NKTR-214: BEMPEG Results: BEMPEG and NIVO vs. Sunitinib or Cabozantinib in RCC Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Comparing Adjuvant Atezolizumab vs. Placebo in RCC Patients at High Risk of Recurrence: IMmotion010 Phase 3 Trial Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) TiNivo-2 Trial: Tivozanib Plus Nivolumab vs. Tivozanib Alone in RCC Mar 27, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Molecular Profiling of RCC Tumors in S-TRAC Anti-Angiogenic Adjuvant Therapy Trial Mar 27, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Phase 3 Trial of Pembrolizumab and Belzutifan for ccRCC: LITESPARK-022 Mar 27, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Savolitinib + Durvalumab Monotherapy for Genomic PRCC Abnormalities Mar 27, 2023
